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Two recently published articles from Siegers and colleagues detail both a novel human gamma delta T cell (GDTc)
expansion protocol and a bioluminescent xenograft model of Ph
+ leukemia, in which GDTc adoptive therapy was tested.
Additionally, B-cell chronic lymphocytic leukemia-derived cells were newly identified as targets of preferentially
expanded Vdelta1 GDTc.
Anti-Leukemia Activity of Human
Gamma Delta T Cells
Once an obscure cell type receiving little
attention, gamma delta T cells (GDTc) are
now coming into their own, as new studies
are published at an ever-increasing rate.
GDTc are immunosurveillance cells, com-
prising 2–5% of circulating lymphocytes
in humans. Ensslin initially reported on
MHC-unrestricted GDTc lysis of tumor
cell lines.
1 We have since learned that
GDTc recognition and tumor lysis can
be mediated by T cell antigen receptor
(TCR), the natural killer receptor
NKG2D, as well as fas-fasL interactions,
depending on GDTc subset and target.
Promising reports from recent clinical
trials support the use of GDTc as
immunotherapeutic agents; either via
adoptive transfer
2 or in vivo stimulation




While the autologous setting is preferable
for adoptive transfer, a report of allo-
transplantation without the incidence of
graft-vs.-host disease suggests that this is
also clinically feasible.
5
The study of GDTc has recently been
rendered more accessible with the advent
of magnetic cell separation allowing posi-
tive or negative selection of GDTc from
blood or tissues. With the ultimate goal of
clinical translation, we used this techno-
logy to develop a novel protocol to isolate
human GDTc from peripheral blood
and expand pure populations to clinically
relevant numbers, without the use of
irradiated feeder cells. Additionally, we
identified new GDTc subset-specific tar-
gets and presented results from preclinical
immunotherapy experiments.
6,7
Our GDTc expansion protocol expands
both Vgamma9Vdelta2 GDTc (Vd2) and
also the lesser-prevalent Vdelta1 GDTc
(Vd1) subset from human blood.
6 A
correlation between duration of initial
GDTc exposure to Concanavalin A
(ConA) and expansion of Vd1 was evident
(Fig.1A). Bartkowiak and colleagues
reported an expanded population of
Vd1 in the blood of B-CLL patients.
8
Thus, using mixed Vd1/Vd2 cultures, the
CD107 mobilization assay
9 was employed
to simultaneously test activation of GDTc
subsets against Philadelphia chromosome
positive (Ph
+) or B-cell chronic lympho-
cytic leukemia (B-CLL)-derived cells.
Indeed, this approach could be applied
to any target of interest. While Ph
+ EM2
cells only activated Vd2, both Vd1 and
Vd2 were activated by B-CLL-derived
MEC1 and TMD2 (Fig.1B), thus obvi-
ating the need to separate subsets for
possible future autologous cellular therapy
of B-CLL. An interesting line of study
made uniquely possible by generation of
mixed cultures is the influence exerted
by one GDTc subset on the other; for
example, one could explore whether Vd2
activation suppresses Vd1.
Finally, some indications as to which
receptors play a role in GDTc cytotoxicity
against their targets were obtained by
correlating surface marker expression with
differential cytotoxicity exhibited by a
panel of Vd1 and Vd2 clones. TCR,
CD56 and CD95 expression correlated
with Vd1 cytotoxicity, while both TCR
and NKG2D were implicated in that of
Vd2. Although perhaps unconventional,
using this panel of clones proved advant-
ageous over the antibody blocking experi-
ments typically employed to elucidate
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mechanism. Initial attempts at blocking
failed when FcR-mediated apoptosis
occurred in B-CLL-derived cells, incited
even by isotype control antibodies. Further
verification of results via blocking will
require the generation of Fab fragments.
Comparing antigen expression on target
cell lines in parallel provided additional
information. The absence of HLA class I
on the surface of EM2eGFPluc cells
pointed to the “missing self” mechanism
by which Daudi lymphoma cells are killed
by Vd2.
10 TRAILR1 expression was
elevated on B-CLL derived cell lines but
not EM2eGFPluc, suggesting involvement
of this surface antigen in Vd1 cytotoxicity.
Much work lies ahead to further elucidate
these cytotoxic mechanisms.
Our other study focused on expanding
Vd2 GDTc for use in a novel biolumi-
nescent xenograft model of Ph
+ leukemia.
7
EM-2 cells expressing eGFP and luciferase




(Fig.1C), closely emulating human
pathogenesis, with leukemia engraftment
restricted largely to the bone marrow,
as monitored in live mice via IVIS
1
technology (Fig.1D,I nV i v oI m a g i n g
System, Xenogen). Expanded GDTc were
cytotoxic to Ph
+ leukemia cell lines in vitro
and thus administered in vivo with the goal
of eradicating leukemia. Intraperitoneal
injection elicited enhanced GDTc engraft-
ment compared with IV. Although different
dosages were attempted, no apparent sur-
vival advantage was achieved. However,
reduced leukemia burden was evidenced in
some treated mice. In the absence of an
intact immune system, tumor burden
quickly progressed to a blast crisis state,
overwhelming GDTc. Potential improve-
ments for future studies include: lowering
the initial leukemia dose; increasing the
number and frequency of GDTc admini-
stration; raising IL-2 doses; or injecting
GDTc in the context of whole peripheral
blood mononuclear cells.
We have reported on a new protocol
that can be manipulated to preferentially
expand Vd1o rV d2 subsets from human
blood. Vd1 are cytotoxic to B-CLL-
derived cells, suggesting that Vd1 may
represent a novel cellular therapy for
B-CLL. Vd2 targeting of Ph
+ leukemia
cells was demonstrated and immuno-
therapy experiments performed in a novel
bioluminescent xenograft model of Ph
+
leukemia. Despite the disappointing
survival outcome of preclinical therapy
experiments, decreased leukemia burden
in some treated mice supports this line of
investigation. Especially promising was
detection of GDTc in the bone marrow
of treated mice at the experimental end-
point, indicating GDTc localization to
tumors, though whether migration was
truly targeted was not addressed. The
report of both a new GDTc expansion
protocol and bioluminescent Ph
+ leuke-
mia model provides further tools with
which we can contribute to the growing
body of evidence supporting the develop-
ment of GDTc as immunotherapeutic
agents targeting leukemia.
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Figure1. (A) Gamma delta T cells (GDTc) isolated from human blood were cultured for six to eight
days in complete medium containing Concanavalin A (ConA). Vdelta1 (Vd1) or Vdelta2 (Vd2) subset
prevalence in expanded culture correlated with the duration of exposure to ConA. (B) Vd2 GDTc are
cytotoxic to EM-2eGFPluc cells, Ph
+ leukemia cells transduced with a lentiviral vector encoding
eGFP and luciferase. Both Vd1 and Vd2 are cytotoxic to B-CLL-derived MEC1 and TMD2 cell lines.
(C) The bioluminescent xenograft Ph
+ leukemia model was established via intravenous (IV) injection
of EM-2eGFPluc cells. Vd2 GDTc therapy was investigated; infusion of GDTc intraperitoneally gave
rise to better engraftment than when GDTc were injected IV. (D) Leukemia progression was
monitored in vivo via IVIS
1 technology (In Vivo Imaging System, Xenogen). Shown here are
representative examples of treated and leukemia-bearing mice. Red circles are regions of interest
from which bioluminescence values were quantified.
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